Wang et al. observed low expressions in 56.3% of cases and more negative expression in advance disease stage.24 Cao et al. noted down regulation of ANXA1 in 79% of BC cases.5 While Deng et al. observed 80% down regulation.25 This evidence concerns the gene ANXA1 and breast cancer.